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Cancer genetic heterogeneity offers a wide reper-
toire of molecular determinants to be screened as
therapeutic targets. Here, we identify potential anti-
cancer targets by exploiting negative genetic inter-
actions between genes with driver loss-of-function
mutations (recessive cancer genes) and their func-
tionally redundant paralogs. We identify recessive
genes with additional copies and experimentally
test our predictions on three paralogous pairs. We
confirm digenic negative interactions between two
cancer genes (SMARCA4 and CDH1) and their corre-
sponding paralogs (SMARCA2 and CDH3). Further-
more, we identify a trigenic negative interaction
between the cancer gene DNMT3A, its functional
paralog DNMT3B, and a third gene, DNMT1, which
encodes the only other human DNA-methylase
domain. Although our study does not exclude other
causes of synthetic lethality, it suggests that func-
tionally redundant paralogs of cancer genes could
be targets in anticancer therapy.INTRODUCTION
The results of cancer genome resequencing show that most
genes with driver alterations (i.e., cancer genes) are tumor
and even sample specific (Ciccarelli, 2010; Vogelstein et al.,
2013). Such high genetic heterogeneity explains why very
few drugs are effective for a large spectrum of cancers,
whereas the most powerful therapies are tailored to the ge-
netics of the individual tumors (Black and Morris, 2012). Cancer
genes have thus been thoroughly studied to identify targets of
anticancer therapy. For example, large efforts have been
devoted to identify synthetic lethal interactions between knownCell Recancer genes such as KRAS (Barbie et al., 2009), EGFR (Dong
et al., 2010), BRCA1, and BRCA2 (Bryant et al., 2005; Farmer
et al., 2005). In this latter case, clinical trials have been de-
signed to treat BRCA-mutated cancers with inhibitors of
PARP1, which has a negative interaction with BRCA genes
(Ashworth, 2008).
Here, we tested the hypothesis that paralogs of cancer
genes, i.e., genes that originated via gene duplication, might
act as negative interactors due to functional redundancy be-
tween multiple gene copies. Negative genetic interactions
between paralogs exist in yeast where the deletion of dupli-
cated genes significantly reduces cell fitness, whereas the
deletion of only one paralog leads to no phenotypic change
(VanderSluis et al., 2010). If similar negative interactions occur
in human, paralogs of cancer-promoting genes could be
used as specific targets to block tumor growth. To test this
hypothesis, we identified a list of putative cancer gene interac-
tors and experimentally blocked the functional paralogs of
three of them (SMARCA4, CDH1, and DNMT3A), as a proof
of principle. In the case of SMARCA4 and CDH1, paralog
silencing significantly reduced cell proliferation only in cancer
cell lines where the cancer gene was mutated. In the case of
DNMT3A, only the concomitant silencing of all functionally
redundant genes—two of which were paralogs and one
shared a functional domain—led to significant decrease in
cell proliferation.
RESULTS
Identification of Paralogs of Recessive Cancer Genes
Dominant and recessive cancer genes roughly correspond
to oncogenes and tumor suppressors, respectively, because
oncogenes usually, but not always, require heterozygous-
activating mutations to exert their role in the disease. Tumor
suppressors, instead, need inactivation of both alleles to
totally impair their anticancer function (Vogelstein and Kinzler,
2004). Given this difference, negative genetic interactions dueports 5, 1519–1526, December 26, 2013 ª2013 The Authors 1519
Figure 1. Predicted Effect of the Impairment of a Recessive Gene
and Its Paralog on Tumor Growth
In normal cells (green), both paralogs are functional (left panel). Mutations
in the recessive gene lead to loss of function and tumorigenesis (central panel).
Blocking the functional paralog (for example, via RNAi) leads to complete
loss of function. This causes decreased proliferation only in cancer cells
because normal cells have the functional recessive gene (right panel). See also
Table S1.to functional compensation should preferentially involve dupli-
cated recessive cancer genes because the loss of func-
tion can be at least partially rescued by the paralog (Figure 1).
As a consequence, silencing the paralog of a duplicated
recessive gene should selectively affect the cancer cells that
bear the inactivated gene but not the normal counterpart
(Figure 1).
To test this hypothesis, we identified the paralogs of 99
recessive cancer genes (Futreal et al., 2004), defined as
additional gene copies covering at least 20% of the protein
length (see Experimental Procedures). Of 99 genes, 23 were
duplicated (23.2% of the total, Table S1). This was a significantly
lower fraction compared to other human genes (38.5%; p =
0.002, Fisher’s exact test) and confirmed the tendency of cancer
genes, and in particular of recessive genes, to retain only one
gene copy (D’Antonio and Ciccarelli, 2011; Rambaldi et al.,
2008). Interestingly, in more than 65% of cases, we found sup-
port from the literature for functional compensation between
recessive genes and their paralogs (Table S1).
To further validate our hypothesis, we experimentally tested
the predicted negative genetic interactions among three reces-
sive genes (SMARCA4, CDH1, and DNMT3A) and their corre-
sponding paralogs (SMARCA2, CDH3, and DNMT3B). These
genes were selected because they had (1) only one paralog,
thus avoiding having to experimentally silence multiple gene
copies, (2) published evidence of functional redundancy with
their paralogs, and (3) cancer cell lines with homozygous non-
silent mutations available for screening (Table S1). Although
these three cases constituted the best candidates to test our
hypothesis, we also predict negative genetic interactions be-
tween the other recessive genes and their paralogs. For all three
genes, we compared the effect of silencing the corresponding1520 Cell Reports 5, 1519–1526, December 26, 2013 ª2013 The Autparalog on the proliferation of the mutated cancer cell line and
of the wild-type control.
SMARCA2 and CDH3 Engage Negative Genetic
Interactions with the Tumor Suppressors SMARCA4 and
CDH1
SMARCA4 and SMARCA2 encode two mutually exclusive DNA-
dependent ATPases of the SWI/SNF complex (Reisman et al.,
2009). SMARCA4- and SMARCA2-containing complexes are
functionally redundant in adult tissues, where one paralog is
able to compensate for the loss of the other (Willis et al., 2012).
SMARCA4 is a known tumor suppressor in several primary
tumors (Rodriguez-Nieto et al., 2011) and particularly in non-
small-cell lung cancers (Reisman et al., 2003). SMARCA2
knockout mice, instead, do not show any increased predisposi-
tion to cancer (Bultman et al., 2008).
We silenced SMARCA2 in two glioblastoma cell lines: one
with a SMARCA4 homozygous-truncating mutation that re-
moves the protein bromodomain (GAMG), and the other with
the wild-type gene (LN405, Figure 2A). Upon silencing via
transient RNAi, SMARCA2 expression decreased in both cell
lines (Figure 2B). However, whereas SMARCA2 silencing sig-
nificantly reduced cell proliferation in SMARCA4 mutated cells,
it had no appreciable effects on the proliferation of SMARCA4
wild-type cells (Figure 2C). To verify the long-term effect of
SMARCA2 silencing, we blocked its expression in GAMG and
LN405 cell lines using a lentiviral vector that stably expressed
an anti-SMARCA2 shRNA (Figure 2D). The colony assay showed
severe proliferation reduction in GAMG cells, whereas no differ-
ence was detected in LN405 cells (Figures 2E and S1). As
a further confirmation, we silenced SMARCA4 and SMARCA2
simultaneously in LN405 cells (Figure 2F) and observed that
cells that did not express either paralog had significantly
decreased proliferation rate as compared to wild-type cells.
Cells with only one blocked gene did not show any difference
(Figure 2G). Altogether, our results sustain the presence of a
negative genetic interaction between SMARCA4 and SMARCA2
that is not cell line dependent.
As a second case study, we tested the negative genetic
interaction between CDH1 and CDH3, which encode members
of the type 1 cadherin family (Hulpiau and van Roy, 2009; Saito
et al., 2012). The two paralogous genes have the same structure
and function, althoughCDH1 is tissue specific, whereasCDH3 is
widely expressed (Saito et al., 2012). Although there is no evi-
dence of CDH3 involvement in cancer, CDH1 is a driver of
epithelial tumors (Mastracci et al., 2005; Shah et al., 2012). We
first confirmed the presence of theCDH1 homozygous nonsense
mutation in the breast cancer cell line ZR75-30, which results in
the loss of more than 70% of the protein, and its absence in the
control cells (ZR75-1, Figure 3A). We then inhibited CDH3
expression via transient RNAi in both cell lines (Figure 3B) and
observed significant decrease in cell proliferation only in the
cell line with the mutated CDH1 (Figure 3C).
In summary, our experiments confirmed the predicted nega-
tive genetic interactions between both pairs of recessive genes
and their functional paralogs. In both cases, silencing the cancer
gene paralog reduced cell proliferation only when the recessive
gene was also mutated.hors
Figure 2. Negative Interaction between SMARCA2 and SMARC4 Genes
(A) Domain composition of SMARCA4 (NP_001122316) and SMARCA2 (NP_003061). SMARCA4-truncating mutation in the GAMG cell line (red arrow) was
confirmed with Sanger.
(B) RT-PCR measuring the effect of siRNA oligos on SMARCA2 gene expression, as compared to scrambled.
(C) Proliferation assay of anti SMARCA2 siRNA-treated cells, as compared to scrambled.
(D) SMARCA2 expression levels measured by RT-PCR upon stable RNAi for SMARCA2, as compared to empty vector.
(E) Long-term effect of SMARCA2 silencing on cell proliferation as assessed by colony assay. Number of colonies in each plate is reported. The comparison of
colony areas is shown in Figure S1.
(F) Expression levels of SMARCA4 and SMARCA2 in LN405 cells upon silencing of only SMARCA4, only SMARCA2, and of both genes as compared to
scrambled.
(G) Proliferation assay of cells treated with only anti-SMARCA4 siRNA, only anti-SMARCA2 siRNA, and both siRNAs.
Two biological replicates were made for each experiment, except for the double KD where three replicates were made. Mean and SE refer to the counts of BrdU-
positive cells across several images of one replicate. Student’s t test was performed between scrambled and silenced cells.
See also Figure S1 and Table S2.
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Figure 3. Negative Interaction between CDH1 and CDH3 Genes
(A) Domain composition of CDH1 (NP_004351) and CDH3 (NP_001784).
Nonsense mutation of CDH1 in ZR75-30 (red arrow) and wild-type gene in
ZR75-1 were confirmed with Sanger sequencing.
(B) RT-PCR of CDH3 upon treatment with anti-CDH3 siRNA oligos, as
compared to scrambled.
(C) Proliferation assay byBrdU incorporation of anti-CDH3 siRNA-treated cells.
Mean and SE refer to the counts of BrdU-positive cells across several images
of one replicate. Student’s t test was performed between scrambled and
silenced cells.
See also Table S2.Trigenic Negative Interaction Occurs among the Tumor
Suppressor DNMT3A, Its Paralog DNMT3B, and the
Residual Functional Compensator DNMT1
DNMT3A and DNMT3B are functionally redundant genes
(Pawlak and Jaenisch, 2011) that encode two de novo methyl-
transferases responsible for the establishment of themethylation
pattern during embryonic development (Jones and Liang, 2009).
In adult tissues, DNMT3A and DNMT3B methylate newly repli-
cated CpG sites and repetitive elements (Jones and Liang,
2009). Inactivating mutations in DNMT3A are found in 25% of
acute myeloid leukemia, where they correlate with poor survival
(Ley et al., 2010). To date, no evidence links DNMT3Bmutations
to cancer.
In OCI-AML2 leukemia cells, the homozygous mutation of
DNMT3A leads to amino acid substitution in the DNA-methylase
domain (Figure 4A). We stably silenced the expression of the
cancer gene paralog (DNMT3B) in the mutated cell line and in
the wild-type control (AML193, Figure S2A). However, unlike1522 Cell Reports 5, 1519–1526, December 26, 2013 ª2013 The Autfor SMARCA4 and CDH1, in this case, we detected no effects
on cell proliferation in either cell line (Figures S2B and S2C),
thus suggesting that no direct negative genetic interactions
occur between DNMT3A and DNMT3B. One possible reason
could be that the missense mutation in DNMT3A is able to drive
tumorigenesis (Renneville et al., 2012) but not to abolish the gene
function. Therefore, no functional compensation is required. An
alternative and intriguing explanation could be the presence of
a third gene that may further compensate for the lack of function
upon impairment of DNMT3A and DNMT3B. This scenario was
suggested by the observation that only one other human gene
(DNMT1) encodes a DNA-methylase domain. DNMT1 does not
share any sequence conservation with DNMT3A and DNMT3B,
and the encoded protein has a different domain composition
(Figure 4B). As a consequence, DNMT1 is not a gene that
evolved via gene duplication of DNMT3A and DNMT3B. Despite
the overall lack of sequence conservation, also DNMT1 encodes
a divergent DNA-methylase domain that nevertheless may
replace the methylase activity in case of impairment of DNMT3A
and DNMT3B. As a first indication that this may indeed be the
case, we detected DNMT1 overexpression when both genes
were silenced as compared to the expression levels when only
DNMT3B was blocked (Figure 4C). To verify the effect of the
silencing of all three genes, we stably silenced DNMT1 in the
OCI-AML2 cell line already treated with anti-DNMT3B shRNA
(Figure 4D), therefore establishing cancer cells without functional
DNA methylases. This led to decreased cell proliferation (Fig-
ure 4E) as detected by FACS analysis. As a comparison, we
stably silenced DNMT1 alone in the AML193 (Figure 4F).
Although also in this case we observed a decreased cell prolifer-
ation, the comparison of the relative decrease of bromodeoxyur-
idine (BrdU)-positive cells in the two cell lines showed that the
cumulative effect of blocking the three genes was significantly
higher than blocking only DNMT1 (Figure 4G). The synergistic
DNMT function is therefore essential for cell viability, and a tri-
genic negative interaction exists among the three genes.
DISCUSSION
In this paper, we investigated negative genetic interactions
that may occur between cancer genes and their paralogs. We
focused in particular on duplicated recessive genes because
they are mostly affected by loss-of function mutations, and
thus, they are predisposed to negative genetic interactions due
to functional redundancy (VanderSluis et al., 2010). However,
this does not exclude negative genetic interactions between
dominant cancer genes and their paralogs because even gain-
of-function mutations may lead to modification of the original
gene function. Thus, paralogs of dominant cancer genes might
act as functional compensators. Similarly, single-copy cancer
genes may also engage in negative genetic interactions with
nonparalogous genes. For example, compensatory synthetic
lethality has been described between the dominant and
singleton cancer gene EGFR and members of the NOTCH
pathway (Dong et al., 2010). Therefore, this study tested the
hypothesis of genetic interactions between functionally redun-
dant paralogs but does not exclude other causes of synthetic
lethality.hors
Figure 4. Functional Compensation among DNMT3A, DNMT3B, and DMT1 Genes
(A) Domain composition of DNMT3A (NP_072046) and DNMT3B (NP_008823).DNMT3Amissensemutation (red arrow) in OCI-AML2 and wild-type sequences in
AML193 were confirmed with Sanger.
(B) Domain composition of DNMT1 (NP_001124295).
(C) RT-PCR of DNMT1 in AML193 and in OCI-AML2 cell lines already treated with anti-DNMT3B shRNAs.
(D) RT-PCR of DNMT1 upon silencing with anti-DNMT1 shRNAs.
(E) Fraction of BrdU-positive cells as detected by FACS in anti-DNMT1 and anti-DNMT3B shRNA OCI-AML2 cells.
(F) Fraction of BrdU-positive cells as detected by FACS in anti-DNMT1 shRNA AML193 cells.
(G) Relative decrease of BrdU-positive cells after normalization for the basal proliferation rate of AML193 and OCI-AML2, respectively.
Statistical significance was assessed using chi-square test. All experiments were made in duplicate; the results of only one replicate are shown.
See also Figure S2 and Table S2.Using a variety of assays and different genetic backgrounds,
we confirmed digenic negative genetic interactions in two tested
gene pairs (SMARCA4 andCDH1) that act as tumor suppressors
in a large spectrum of epithelial tumors (Forbes et al., 2011).
Inhibition of their paralogs could therefore arrest or at least
reduce tumor growth in several cancer types. Furthermore,
both SMARCA2 and CDH3 have been already exploited as
drug targets. For example, SMARCA4 and SMARCA2 knock-Cell Redown cells are hypersensitive to cisplatin (Kothandapani et al.,
2012), a chemotherapeutic drug that increases the DNA
damage levels by crosslinking DNA (Pruefer et al., 2008). Simi-
larly, CDH3 is the target of the monoclonal antibody PF-
03732010 in both cell-based assays and tumor models (Zhang
et al., 2010), and phase 1 clinical trials on human patients with
cancer are currently ongoing. Although these preliminary data
are encouraging, additional experiments are needed to assessports 5, 1519–1526, December 26, 2013 ª2013 The Authors 1523
the real efficacy of gene blocking. For example, in cell lines, we
observed a statistically significant reduction but never a
complete abolishment of cell proliferation. Direct quantification
of tumor growth upon paralogous gene blocking in lesions
with mutations in SMARCA4 or CDH1 is therefore required.
Another factor to consider is the possible multiplicative effect
due to functional redundancy among several genes. A good
example of this is the trigenic interaction that we detected
among DNMT3A, DNMT3B, and DNMT1. The latter has no
paralogy relationships with either DNMT3A or DNMT3B but
was nevertheless able to rescue the function due to the meth-
ylase domain. In this case, all three genes, and not only the
two paralogs, must be blocked in order to observe a major effect
on cell proliferation. Although case by case validation is required
in order to assess whether single genes can be used as thera-
peutic targets, our study provides a proof of principle that nega-
tive genetic interactions exist between cancer genes and their
paralogs.
EXPERIMENTAL PROCEDURES
Identification of Duplicated Recessive Cancer Genes
A list of 103 recessive cancer genes was retrieved from the Cancer Gene
Census (frozen on November 15, 2011) (Futreal et al., 2004). Four genes
(CBL, IKZF1, CREBBP, and PRKAR1A) were discarded because they were
defined both as dominant and recessive, thus leading to a total of 99 recessive
cancer genes.
To identify duplicated recessive cancer genes, amodified version of our pre-
viously developed method (Rambaldi et al., 2008) was applied. In brief, protein
sequences from RefSeq v.51 (Pruitt et al., 2009) were aligned to the human
reference genome (hg19) with BLAT (Kent, 2002), with parameters t = dnax,
q = prot, minimal score = 0, and minimal identity = 0. The direct alignment
of human proteins to the human genome avoided problems of multiple gene
isoforms, missing paralogs, and low sensitivity. A ‘‘hit’’ was defined as the
portion of the human genome that aligned to the original protein sequence.
The hit with the highest coverage (i.e., fraction of aligned protein sequence)
was defined as the original gene locus. All additional hits covering at least
20% of the original protein length and mapping on a transcribed locus were
considered as duplications. Out of the 33,398 initial proteins, 19,045 entries
corresponded to unique human genes (i.e., genes mapping to distinct and
nonoverlapping genomic loci). The remaining 14,353 sequenceswere isoforms
(12,915 entries), mapped on noncanonical or mitochondrial chromosomes
(1,404 entries), or did not align to the human genome (34 entries). Of 19,045
genes, 7,323had at least oneparalog, and23were duplicated recessive genes.
Selection of Gene Pairs for Experimental Validation
Information about mutations in cancer cell lines was downloaded from
COSMIC v.57 (frozen on January 18, 2012) (Forbes et al., 2011) and from the
Cell Line Project v.67 (http://www.sanger.ac.uk/genetics/CGP/CellLines/).
Mutation data integration from the two sources pinpointed 665 cell lines with
homozygous mutations in 36 recessive genes, 10 of which were duplicated.
Of those, three genes (SMARCA4, CDH1, and DNMT3A) were used for exper-
imental validation because they had only one paralog and literature support of
functional redundancy (Table S1). Protein domains in these genes were anno-
tated using SMART (Letunic et al., 2012).
DNA was extracted from each of the six cell lines (GAMG, LN405, ZR75-30,
ZR75-1, OCI-AML2, and AML193) using DNeasy Blood & Tissue Kit (Qiagen),
following the manufacturer’s procedures. PCR amplification and Sanger
sequencing were performed to confirm the homozygous mutations reported
in the literature (Table S2).
Quantitative RT-PCR
In each cell line, total RNA was collected using TRIzol (Life Technologies),
according to the manufacturer’s protocol, quantified, and quality controlled.1524 Cell Reports 5, 1519–1526, December 26, 2013 ª2013 The AutReverse transcription was performed on 500 ng RNA with SuperScript VILO
cDNA Synthesis Kit (Life Technologies). Changes in gene expression were
detected using Applied Biosystems Fast SYBR Green Master Mix. Each
real-time PCR assay was performed in triplicate using an Applied Biosystems
7500 Fast Real-Time PCR System Thermal Cycler. The fold enrichment was
calculated as log2 of the mean fold over the control, using b-actin as house-
keeping gene (Table S2).
Transient RNAi, BrdU Assay, and Immunofluorescence
Two independent RNAi oligos specific for SMARCA2 andCDH3were retrieved
from Stealth Select RNAi small interfering RNA (siRNA; Life Technologies). An
unrelated oligo was used as control (Table S2). Transfection was performed
with QIAGEN-HiPerFect Transfection Reagent, according to the manufac-
turer’s protocol. All RNAi oligos were used at a final concentration of 50 nM.
Each transfection mix was incubated with cells for 16 hr at 37C and then
replacedwith freshmedium. Cells were plated (100,000/well in a 6-well plate)
on gelatin-coated coverslips to reach a final concentration of 0.5% w/v. BrdU
assay was performed 48 hr after transfection. BrdU was directly added to the
medium at a final concentration of 10 mM and incubated with cells for different
time periods, according to their proliferation rate (1 hr for LN405/GAMG, 6 hr
for ZR75-30/ZR75-1). Cells were then fixed for 10 min at room temperature
with paraformaldehyde 4%w/v (in PIPES buffer) and permeabilized with Triton
X-100 0.1% for 10 min at room temperature. The primary antibody mix was
prepared in PBS-BSA 3% w/v, according to the following recipe: mouse
anti-BrdU antibody (1:40 v/v), Promega DNase (1:10 v/v), Promega DNase
Buffer (1:10 v/v), and MgCl2 (final concentration, 5 mM) and incubated for
45 min at room temperature in a humid chamber. The secondary antibody
mix (anti-mouse Cy3, 1:400 v/v in PBS-BSA 3% w/v) was incubated for an
additional 45 min at room temperature, light protected. After DAPI staining,
the coverslips were mounted with Moviol medium and observed by optical
fluorescence microscope. A total of 5–15 images from each cell culture were
acquired, and the fraction of BrdU-positive cells was counted independently
for each image. Student’s t test was performed between scrambled and KD
cells. Two biological replicates were made for each experiment, except for
the double KD of SMARCA2 and SMARCA4, where three replicates were
made.
Stable RNAi and Colony Assay
In case of SMARCA2, DNMT3B, and DNMT1, gene expression was blocked
with stable RNAi using pSICOR vectors (from the Jackson Laboratory,
http://web.mit.edu/jacks-lab/protocols/pSico.html) to clone specific shRNA
oligos in the target cell lines. Two different 50 phosphorylated, PAGE-purified
oligos were designed for this gene using the program PSICOLIGOMAKER
1.5 (Reynolds et al., 2004) (Table S2). Oligo cloning was performed according
to the protocol from The Jacks Lab (http://web.mit.edu/jacks-lab/protocols/
pSico.html). Briefly, oligos were diluted in 23 annealing buffer (200 mM potas-
sium acetate, 60 nM HEPES-KOH [pH 7.4], 4 mM Mg-acetate), annealed for
4 min at 95C, followed by 10 min at 70C, and slowly cooled down to 4C.
Then pSICOR vector was digested with HpaI and XhoI (New England Biolabs)
and ligated with the oligo pairs for 3 hr at room temperature. A total of 2 ml of
each ligation was transformed using One Shot TOP10 Chemically Competent
Escherichia coli (Life Technologies), and positive clones were checked by
XhoI-XbaI digestion. Positive clones were selected for the presence of
400 bp fragment (compared with 350 bp of the empty vectors) and sequenced
using Sanger sequencing for confirmation (Table S2). 293T amphotropic cells
were transfected using Calcium Phosphate with a DNA mix containing viral-
packaging constructs and pSICOR-sh constructs for each of the three genes.
Each time, a pSICOR-empty vector was used as a control. At 48 hr after trans-
fection, viral supernatant was collected and used to infect target cells (GAMG
and LN405 for SMARCA2; OCI-AML2 and AML193 for DNMT3B and DNMT1).
Stably infected cells were selected using 1 mg/ml puromycin for GAMG, LN405
and 4 mg/ml for OCI-AML2, AML193 48 hr after the infection. Two biological
replicates were made for each experiment.
Stably transfected GAMG and LN405 cells were plated in 10 cm plates at
low density (1,000, 5,000, or 10,000 cells) in complete medium with puromycin
and grown at 37C for 14 days. Colonies were stained with crystal violet solu-
tion (1% w/v in ethanol 35%) and fixed at room temperature.hors
FACS Analysis
To assess the effect of sh-DNMT3B and sh-DNMT1 on cell proliferation of the
two suspension cell lines (OCI-AML2 and AML193), cells were plated in T-25
flasks at the typical density (http://www.lgcstandards-atcc.org). BrdU assay
was performed 16 hr after plating and incubated with cells for 3 hr. Cells
were then fixed with cold 70% ethanol, dropwise while vortexing (1 ml/million),
washed in PBS-BSA 1% w/v, and permeabilized with denaturing solution (2N
HCl) for 25 min at room temperature. After neutralization with 3 vol sodium
borate 0.1 M (pH 8.5) for 5 min at room temperature, cells were washed with
PBS-BSA 1%w/v and incubated in primary antibody mix for 1 hr at room tem-
perature, light protected. The primary antibody mix (mouse anti-BrdU anti-
body, 1:5 v/v) was prepared in PBS-BSA 1% w/v. The secondary antibody
mix (anti-mouse FITC, 1:50 v/v in PBS-BSA 1% w/v) was incubated for an
additional hour at room temperature, light protected. Finally, cells were incu-
bated with propidium iodide (PI) solution (final concentration of 2.5 mg/ml, in
PBS) plus RNase (1:40 v/v) overnight at 4C. After incubation, they were
analyzed by FACS for PI content, and the fraction of BrdU-positive cells
over the total was calculated. Two biological replicates were made for each
experiment.
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